^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BRAF wild-type

i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
4d
Location based BRAF V600E mutation status and dimension patterns of sporadic thyroid nodules: a population-based study. (PubMed, BMC Cancer)
Interestingly, among patients with PTC with lymph node metastasis (LNM), right-side-affected LNM was significantly more common than left-side-affected LNM, which implies a biased regional LNM of right-side-located thyroid nodules (p = 0.0007). The size of BRAF-V600E mutated or right-lobe located nodules was significantly larger than that in the control group (p = 0.0156), and patients with a BRAF V600E mutation were considerably younger than those with wild-type BRAF.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF wild-type
7d
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status. (PubMed, Front Immunol)
Brain metastasis has a negative impact on long-term survival in BRAF-mutated, but not in BRAF-wildtype patients. Investigation of molecular features of brain metastases in BRAF-mutated vs. BRAF-wildtype melanomas may lead to new insights in tumor biology and may yield new therapeutic approaches.
Journal • IO biomarker
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • LDH elevation • BRAF wild-type
15d
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (clinicaltrials.gov)
P2, N=34, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jan 2026
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • EGF (Epidermal growth factor)
|
KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61
|
Mekinist (trametinib) • omipalisib (GSK2126458)
18d
Trial termination
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)
|
BRAF V600E • HER-2 overexpression • BRAF wild-type • RAS mutation • NRAS wild-type
|
5-fluorouracil • Vectibix (panitumumab)
18d
Extracellular vesicle-mediated gene therapy targets BRAFV600E-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathway. (PubMed, J Nanobiotechnology)
The therapeutic EVs we constructed are effective and specific for the BRAFV600E-mutant CRC. This study provides a novel strategy for the treatment of CRC patients with BRAFV600E mutation.
Journal
|
BRAF (B-raf proto-oncogene) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
|
BRAF V600E • BRAF V600 • BRAF wild-type
20d
Phase classification
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • HER-2 amplification • BRAF V600 • BRAF wild-type
|
Keytruda (pembrolizumab) • NCE 401
21d
BRAF V600E in Cancer: Exploring Structural Complexities, Mutation Profiles, and Pathway Dysregulation. (PubMed, Exp Cell Res)
Further, we have discussed dysregulated pathways associated with mutation of BRAFV600E, which includes MAPK/ERK, PI3K/AKT/mTOR, TP53, DNA damage response, and WNT/β-Catenin from schematic representation. In the current review, we have shown how these dysregulated pathways play pivotal roles in tumorigenesis, tumor progression in BRAF-mutant cancers and highlighted the critical role of BRAF dysregulation in cancer development followed by its therapeutic implications of targeting dysregulated pathways in BRAF-driven malignancies.
Review • Journal
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • mTOR (Mechanistic target of rapamycin kinase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PI3K (Phosphoinositide 3-kinases)
|
TP53 mutation • BRAF V600E • BRAF V600 • BRAF wild-type
25d
A Case of Maintenance Chemotherapy for Appendiceal Carcinoma with Signet-Ring Cell Carcinoma (PubMed, Gan To Kagaku Ryoho)
We experienced a case of cecal cancer with peritoneal dissemination accompanied by signet ring cell carcinoma, where maintenance chemotherapy proved effective.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • HER-2 negative • BRAF wild-type • RAS wild-type • BRAF V600 wild-type
|
5-fluorouracil • leucovorin calcium
26d
BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS). (PubMed, Cancers (Basel))
These findings highlight distinct clinical and prognostic profiles for BRAF V600E and non-V600E mutations, while treatment choice appears to have limited impact on survival in these subgroups or RAS/BRAF wild-type cases.
Observational data • Journal • MSi-H Biomarker
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • RAS (Rat Sarcoma Virus) • CA 19-9 (Cancer antigen 19-9)
|
BRAF V600E • MSI-H/dMMR • BRAF wild-type • RAS mutation • RAS wild-type
|
Avastin (bevacizumab)
27d
Comparison of survival outcomes for patients with Lynch vs non-Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy. (PubMed, Cancer)
Patients with MSI-H CRC treated with ICIs exhibited similar outcomes regardless of germline or somatic MMR mutations. However, the presence of a BRAF V600E mutation was associated with a worse prognosis.
Clinical • Retrospective data • Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
|
BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
|
Keytruda (pembrolizumab)
28d
Trial suspension
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
28d
Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors. (PubMed, J Immunother Cancer)
Overall, our findings suggest a complex interplay between sex and BRAF mutational status that may modulate the activity of ICIs in patients with MSI-H mCRC and pave the way to novel tailored strategies.
Journal • Checkpoint inhibition • Microsatellite instability • MSi-H Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • AR (Androgen receptor)
|
BRAF V600E • MSI-H/dMMR • BRAF mutation • BRAF V600 • BRAF wild-type • RAS mutation
29d
BRAFV600E mutation is associated with better prognoses in radioactive iodine refractory thyroid cancer patients treated with multi-kinase inhibitors: a retrospective analysis of registered clinical trials. (PubMed, Thyroid Res)
RAIR-DTC patients with BRAFV600E mutation treated with apatinib, donafenib, or anlotinib achieved better prognoses compared with patients with wild-type BRAF, indicating that the genetic background may play a role in predicting the efficacy of MKIs therapies.
Retrospective data • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF wild-type
|
Focus V (anlotinib) • AiTan (rivoceranib) • Zepsun (donafenib)
1m
Discovery of novel naphthalene-based diarylamides as pan-Raf kinase inhibitors with promising anti-melanoma activity: rational design, synthesis, in vitro and in silico screening. (PubMed, Arch Pharm Res)
While sorafenib demonstrates strong activity against wild-type B-Raf, it fails to effectively inhibit the mutated form of B-Raf...Additionally, it induced G2/M phase arrest and triggered dose-dependent apoptosis, effectively suppressing both cell proliferation and survival. Compound 9a also exhibited high selectivity for Raf isoforms with minimal off-target effects, underscoring its specificity and therapeutic potential for Raf-driven malignancies.
Preclinical • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF wild-type
|
sorafenib
1m
Performance of Machine Learning Models in Predicting BRAF Alterations Using Imaging Data in Low-Grade Glioma: A Systematic Review and Meta-Analysis. (PubMed, World Neurosurg)
AI models may perform relatively well in predicting BRAF alterations in LGG using imaging data and appear to be capable of high sensitivities and specificities. However, future studies with larger sample sizes implementing different ML or DL algorithms are required to reduce imprecision.
Retrospective data • Review • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type • BRAF fusion
1m
Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study. (PubMed, Anticancer Drugs)
CAPEOX combined with cetuximab differs from the FOLFOX regimen by using oral capecitabine instead of continuous infusion of fluorouracil, offering greater convenience and cost-effectiveness with higher patient acceptance...The two groups achieved similar median PFS (mPFS) and median OS (mOS), with mPFS of 18 months and 12 months, respectively (P = 0.23), and mOS of 33 months and 20 months, respectively (P = 0.21), with no statistically significant differences. The results of this study demonstrated that CAPEOX combined with cetuximab is an equally viable option for first-line treatment of RAS/BRAF wild-type mCRC as FOLFOX combined with cetuximab.
Journal
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
BRAF wild-type
|
Erbitux (cetuximab) • 5-fluorouracil • capecitabine • leucovorin calcium
1m
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis (clinicaltrials.gov)
P1/2, N=30, Not yet recruiting, Brown University | Trial primary completion date: Jan 2025 --> Mar 2026
Trial primary completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
Keytruda (pembrolizumab)
1m
Elucidating the Prognostic Role of BRAF V600E and the Activation Status of the Downstream MAPK Pathway in PTC: A Study from a Tertiary Centre in India. (PubMed, Indian J Endocrinol Metab)
Immunopositivity for pMEK1/2 in most suggests a scope for MEK1-targeted therapy in recalcitrant PTC cases even in the absence of the BRAF mutation. In addition, IHC is a reliable technique for detecting BRAF V600E mutation but needs validation by correlation with molecular studies.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF wild-type
1m
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (clinicaltrials.gov)
P1, N=39, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Sep 2025
Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF wild-type
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Stivarga (regorafenib)
1m
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)
P2, N=169, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jan 2026
Trial completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
1m
Phase II study of pembrolizumab combined with temozolomide as first-line treatment in Chinese patients with metastatic acral melanoma (ChiCTR2100050073)
P2, N=38, Recruiting, Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
Keytruda (pembrolizumab) • temozolomide
1m
Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial. (PubMed, Eur J Cancer)
Combined immunotherapy and hypofractionated radiotherapy did not improve survival compared to historical cohorts. The radiotherapy schedule needs to be optimized in order to improve these results.
P2 data • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF wild-type
|
Opdivo (nivolumab)
1m
Irisin and Metastatic Melanoma: Selective Anti-Invasiveness Activity in BRAF Wild-Type Cells. (PubMed, Int J Mol Sci)
Moreover, gene expression analysis (qPCR) of MMP-2 and MMP-9 and of the fibrinolytic system (uPAR, uPA and PAI-1) highlighted a crucial role of 10 nM r-irisin treatment in the inhibition of pro-invasive systems in BRAFwt/wt. In conclusion, our results may suggest a possible differential role of irisin in melanoma cells.
Review • Journal
|
BRAF (B-raf proto-oncogene) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
BRAF V600E • BRAF V600 • BRAF V600K • BRAF wild-type
1m
KRAS, NRAS, and BRAF Hot-Spot Mutations in Relation to Sidedness of Primary Colorectal Cancer: A Retrospective Cohort Study. (PubMed, Diagnostics (Basel))
These findings suggest that tumorigenesis and mutational processes differ based on tumor sidedness. Further studies are needed to substantiate these findings.
Retrospective data • Journal • Tumor mutational burden
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • BRAF wild-type • RAS wild-type
1m
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort. (PubMed, Clin Colorectal Cancer)
These findings support the use of bevacizumab-based over aflibercept-based regimens as II-line treatment in mCRC, especially in KRAS/NRAS and BRAF wild type tumors.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • BRAF wild-type • NRAS wild-type
|
Avastin (bevacizumab)
2ms
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=232, Active, not recruiting, Genentech, Inc. | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026 | Recruiting --> Active, not recruiting
Enrollment closed • Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • BRAF wild-type
|
Tecentriq (atezolizumab) • migoprotafib (RLY-1971) • omeprazole
2ms
PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers. (PubMed, J Exp Med)
We also demonstrate that melanocyte-specific knockout of PTPN23 significantly inhibits BRAFV600E-driven melanomagenesis. Altogether, our findings demonstrate that targeting PTPN23/PI3KC2α offers a new and viable therapeutic strategy for BRAF-mutant cancers.
Journal
|
BRAF (B-raf proto-oncogene) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)
|
BRAF V600E • BRAF mutation • BRAF V600 • BRAF wild-type
2ms
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population. (PubMed, Ann Oncol)
This exploratory analysis from a randomized phase II study shows a non-significant improvement in TTR from the addition of neoadjuvant panitumumab to peri-operative FOLFOX in RAS/BRAF-wt LACC. Hyperselection with EREG/AREG status was associated with increased efficacy. A dedicated prospective trial within a biomarker selected population is under development.
P2 data • Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • EREG (Epiregulin)
|
BRAF mutation • KRAS wild-type • BRAF wild-type • RAS mutation
|
5-fluorouracil • Vectibix (panitumumab) • leucovorin calcium
2ms
Continuing anti-EGFR monoclonal antibody after secondary resection significantly prolongs overall survival for patients with metastatic colorectal cancer who were responsive to first-line anti-EGFR monoclonal antibody plus chemotherapy doublet. (PubMed, Am J Cancer Res)
A multivariate analysis revealed that postresection anti-EGFR mAb was an independent predictor of prolonged OS. In conclusion, for mCRC patients who have undergone secondary resection after first-line anti-EGFR mAb plus doublet chemotherapy, continuing anti-EGFR mAb may significantly extend OS, regardless of the primary tumor location.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS wild-type • BRAF wild-type • RAS wild-type
2ms
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG). (PubMed, Clin Colorectal Cancer)
Six-month PFS in both arms was consistent with that achieved with FU/bev, whilst the rate was numerically higher for Arm B. Baseline comprehensive geriatric assessments were feasible and OTU was high. Both treatment arms might be suitable in appropriately selected patients.
P2 data • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF wild-type
|
5-fluorouracil • Vectibix (panitumumab)
2ms
Pushing the Boundaries of Minimally Invasive Surgery: Fully Laparoscopic Left Hepatectomy Extended to Segment 8 for Bilobar Colorectal Liver Metastases. (PubMed, Cureus)
The patient underwent six cycles of chemotherapy with FOLFOX (oxaliplatin in combination with 5-fluorouracil and leucovorin), and radiofrequency ablation (RFA) was applied to the lesion in segment VI, resulting in a favorable response in imaging control. In addition to the dissection and section of the middle and left hepatic vein included in the surgical specimen. The patient experienced a rapid postoperative recovery with good liver function, an early hospital discharge, and a quick return to work, highlighting the clear advantages of laparoscopic surgery.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
BRAF wild-type • NRAS wild-type
|
5-fluorouracil • oxaliplatin • leucovorin calcium
2ms
MLH1 gene promoter methylation status partially overlaps with CpG methylator phenotype (CIMP) in colorectal adenocarcinoma. (PubMed, Pathol Res Pract)
Our study demonstrates that pMLH1 hypermethylation, MMRd, BRAFmut and CIMP phenotype do not completely overlap in CRC. These findings further refine the knowledge on the molecular landscape of CRC and may have critical implications also for the clinical management of the disease.
Journal
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • RAS (Rat Sarcoma Virus)
|
BRAF V600E • BRAF V600 • BRAF wild-type • RAS mutation
2ms
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. (PubMed, Future Oncol)
The MOUNTAINEER-03 phase III trial is designed to investigate the efficacy and safety of first-line tucatinib in combination with trastuzumab and modified FOLFOX6 (mFOLFOX6) versus standard of care (mFOLFOX6 plus bevacizumab or cetuximab) in patients with untreated HER2+, RAS WT locally advanced unresectable or mCRC...Key secondary endpoints are overall survival and confirmed objective response rate (according to RECIST v1.1 per BICR). Safety assessments will include surveillance and recording of adverse events, physical examination findings, vital signs, cardiac assessments, Eastern Cooperative Oncology Group performance status, concomitant medications, and laboratory tests.Clinical trial registration: NCT05253651 (ClinicalTrials.gov).
P3 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
HER-2 positive • HER-2 amplification • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type • HER-2 positive + RAS wild-type
|
Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium
3ms
Sarcoidosis-Like Reaction in Melanoma Patients Receiving Immunotherapy or Targeted Therapy. (PubMed, Case Rep Oncol Med)
A 55-year-old woman with Stage IIIb cutaneous melanoma, receiving adjuvant therapy with anti-PD-1, after seven cycles of pembrolizumab, developed mediastinal node enlargement and skin hypodermic nodes...A 48-year-old woman with Stage IIIb BRAF wild-type melanoma, receiving nivolumab every 4 weeks, developed systemic sarcoidosis after seven cycles, primarily affecting extrapulmonary sites...A 65-year-old man with Stage IIIb BRAF-mutant melanoma, receiving dabrafenib and trametinib, developed lung and cutaneous sarcoidosis, presenting with symptoms that led to emergency department admission. In all cases, the MDT played a crucial role in determining the course of treatment and balancing the risks of continuing or suspending cancer therapies while managing SLRs. National and international guidelines were consulted, but tailored decisions by the MDT were essential for optimizing patient care.
Journal • PD(L)-1 Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Mekinist (trametinib) • Tafinlar (dabrafenib)
3ms
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases (clinicaltrials.gov)
P3, N=508, Recruiting, Fudan University | N=386 --> 508 | Trial completion date: Dec 2026 --> Sep 2027 | Trial primary completion date: Dec 2023 --> Mar 2025
Enrollment change • Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
BRAF wild-type
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan
3ms
Circulating Hepcidin Levels Are an Independent Predictor of Survival in Microsatellite Stable Metastatic Colorectal Cancer Patient Candidates for Standard First-Line Treatment. (PubMed, Cancers (Basel))
Our data show that baseline serum levels of hepcidin are an independent risk factor for OS in MSS mCRC patients undergoing standard first-line treatment. Further prospective and extensive studies are needed to confirm and validate our findings.
Journal • Metastases
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
BRAF mutation • BRAF wild-type • RAS mutation
|
Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • leucovorin calcium
3ms
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (clinicaltrials.gov)
P=N/A, N=13, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2025 --> Sep 2025
Trial completion date • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600 • BRAF wild-type
|
Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
3ms
Enrollment open • Enrollment change • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
3ms
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study. (PubMed, Clin Res Hepatol Gastroenterol)
Triplet induction chemotherapy is a treatment of choice in selected patients with SMRC, allowing to adapt the therapeutic strategy to the response and invasiveness of the various sites.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF wild-type • RAS mutation
|
5-fluorouracil • irinotecan • leucovorin calcium
3ms
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study. (PubMed, Mol Oncol)
The randomized FIRE-4.5 (AIO KRK0116) trial compared first-line therapy with FOLFOXIRI (folinic acid, fluorouracil, oxaliplatin, and irinotecan) plus either cetuximab or bevacizumab in B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E-mutant metastatic colorectal cancer (mCRC) patients. Those patients also achieved a significantly greater disease control rate (89% vs 20%; P = 0.008). In conclusion, LB evaluating ctDNA is informative and may help to guide treatment in patients with BRAF V600E-mutated mCRC.
Journal • Circulating tumor DNA
|
BRAF (B-raf proto-oncogene) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
|
BRAF V600E • BRAF V600 • BRAF wild-type • RAS mutation
|
OncoBEAM RAS CRC kit
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
3ms
NCI-2020-02590: Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma (clinicaltrials.gov)
P2, N=3, Terminated, Jonsson Comprehensive Cancer Center | N=28 --> 3 | Trial completion date: Jun 2026 --> Nov 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Nov 2024; poor enrollment
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden)
|
BRAF V600 • BRAF wild-type
|
Opdivo (nivolumab) • Mektovi (binimetinib)
3ms
BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling. (PubMed, Signal Transduct Target Ther)
In vivo studies have shown that BRAFi can enhance human hematopoiesis and erythropoiesis in severe immunodeficient mouse models and alleviate anemia in the Rpl11 haploinsufficiency DBA model, as well as other relevant anemia models. This discovery underscores the role of the MAPK pathway in hematopoiesis and positions BRAFi as a promising therapeutic option for improving hematopoietic reconstitution and treating anemias, including DBA.
Journal
|
RPL11 (Ribosomal Protein L11)
|
BRAF V600E • BRAF V600 • BRAF wild-type